Get the Stockscreener App
1.60
8.84%
0.13
After Hours:
1.60
Inhibikase Therapeutics Inc stock is traded at $1.60, with a volume of 320.50K.
It is up +8.84% in the last 24 hours and down -3.61% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$1.47
Open:
$1.46
24h Volume:
320.50K
Relative Volume:
2.79
Market Cap:
$119.23M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.5112
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
+2.56%
1M Performance:
-3.61%
6M Performance:
-28.89%
1Y Performance:
-39.39%
1-Day Range:
$1.33
$1.76
1-Week Range:
$1.33
$1.76
52-Week Range:
$1.33
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.60 | 109.54M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Will Inhibikase Therapeutics Inc. stock beat EPS estimatesJuly 2025 Momentum & Free Expert Approved Momentum Trade Ideas - newser.com
What makes Inhibikase Therapeutics Inc. stock attractive to growth funds2025 Market Outlook & Risk Managed Investment Signals - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock trades below fair value2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - newser.com
What institutional flow reveals about Inhibikase Therapeutics Inc.Weekly Gains Report & Smart Money Movement Tracker - newser.com
Will Inhibikase Therapeutics Inc. price bounce be sustainable2025 Stock Rankings & Expert Curated Trade Ideas - newser.com
Key resistance and support levels for Inhibikase Therapeutics Inc.2025 Price Momentum & Growth Oriented Trade Recommendations - newser.com
Will Inhibikase Therapeutics Inc. (IQT0) stock top growth indexesTrend Reversal & High Conviction Trade Alerts - newser.com
Is Inhibikase Therapeutics Inc. (IQT0) stock overpriced at current multiplesWeekly Stock Summary & Smart Swing Trading Techniques - newser.com
Will Inhibikase Therapeutics Inc. stock recover after recent dropWeekly Trade Review & Long-Term Capital Growth Ideas - newser.com
Signal strength of Inhibikase Therapeutics Inc. stock in tech scannersTrade Entry Summary & Weekly Watchlist of Top Performers - newser.com
Can Inhibikase Therapeutics Inc. stock reach $100 price target2025 Bull vs Bear & Verified Entry Point Signals - newser.com
Can volume confirm reversal in Inhibikase Therapeutics Inc.Gold Moves & AI Forecast Swing Trade Picks - newser.com
Top chart patterns to watch in Inhibikase Therapeutics Inc.Portfolio Gains Report & Daily Technical Stock Forecast Reports - newser.com
Can Inhibikase Therapeutics Inc. recover in the next quarter2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock is a strong analyst pickJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
Why Inhibikase Therapeutics Inc. stock is a must watch in 2025Earnings Growth Report & Reliable Volume Spike Trade Alerts - newser.com
Analyzing Inhibikase Therapeutics Inc. with risk reward ratio chartsWeekly Trend Recap & Long-Term Safe Investment Plans - newser.com
How to build a dashboard for Inhibikase Therapeutics Inc. stockWeekly Market Summary & Real-Time Volume Triggers - newser.com
Will Inhibikase Therapeutics Inc. stock attract ESG investorsJuly 2025 Retail & Advanced Technical Signal Analysis - newser.com
Can Inhibikase Therapeutics Inc. stock maintain operating marginsPortfolio Value Report & Stepwise Trade Execution Plans - newser.com
Will Inhibikase Therapeutics Inc. (IQT0) stock profit from AI boomJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - newser.com
Is Inhibikase Therapeutics Inc. (IQT0) stock a defensive play amid uncertaintyJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
How Inhibikase Therapeutics Inc. stock compares to growth peers2025 Dividend Review & Community Driven Trade Alerts - newser.com
Earnings visualization tools for Inhibikase Therapeutics Inc.Portfolio Return Summary & Verified Momentum Stock Ideas - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock fits value portfolios2025 Price Momentum & Short-Term Swing Trade Alerts - newser.com
Is Inhibikase Therapeutics Inc. reversing from oversold territoryInsider Buying & Real-Time Market Trend Scan - newser.com
Why Inhibikase Therapeutics Inc. stock appeals to analysts2025 Top Decliners & Daily Profit Focused Screening - newser.com
Tools to monitor Inhibikase Therapeutics Inc. recovery probabilityJuly 2025 Action & Weekly High Potential Alerts - newser.com
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):